Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tacrine hydrochloride
Drug ID BADD_D02104
Description A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.
Indications and Usage For the palliative treatment of mild to moderate dementia of the Alzheimer's type.
Marketing Status approved; investigational; withdrawn
ATC Code N06DA01
DrugBank ID DB00382
KEGG ID D02068
MeSH ID D013619
PubChem ID 2723754
TTD Drug ID D0E6YQ
NDC Product Code Not Available
UNII 4966RNG0BU
Synonyms Tacrine | 9-Amino-1,2,3,4-Tetrahydroacridine | 1,2,3,4-Tetrahydro-9-acridinamine | Tetrahydroaminoacridine | 1,2,3,4-Tetrahydroaminoacridine | Romotal | Tenakrin | THA | Cognex | Tacrine Hydrochloride
Chemical Information
Molecular Formula C13H15ClN2
CAS Registry Number 1684-40-8
SMILES C1CCC2=NC3=CC=CC=C3C(=C2C1)N.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Transient ischaemic attack24.04.06.005; 17.08.04.001--
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary incontinence17.05.01.008; 20.02.02.010--
Urinary retention20.02.02.011--
Urinary tract infection20.08.02.001; 11.01.14.004--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vertigo04.04.01.003; 17.02.12.002--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Self-injurious ideation19.12.01.007--Not Available
Respiratory tract congestion22.02.07.003--Not Available
Transaminases increased13.03.04.036--Not Available
Faecaloma07.01.03.004--Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Prostate cancer21.04.02.002; 16.25.01.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Renal neoplasm20.01.04.004; 16.08.03.001--Not Available
Inner ear disorder04.04.02.002--Not Available
Parkinson's disease17.01.05.010--Not Available
Urinary tract obstruction20.08.01.004--
Psychotic disorder19.03.01.002--
Peripheral venous disease24.04.02.022--Not Available
Anal incontinence17.05.01.021; 07.01.06.029--
The 8th Page    First    Pre   8    Total 8 Pages